TY - JOUR
T1 - Cortical and trabecular bone microarchitecture as an independent predictor of incident fracture risk in older women and men in the Bone Microarchitecture International Consortium (BoMIC)
T2 - a prospective study
AU - Samelson, Elizabeth J.
AU - Broe, Kerry E.
AU - Xu, Hanfei
AU - Yang, Laiji
AU - Boyd, Steven
AU - Biver, Emmanuel
AU - Szulc, Pawel
AU - Adachi, Jonathan
AU - Amin, Shreyasee
AU - Atkinson, Elizabeth
AU - Berger, Claudie
AU - Burt, Lauren
AU - Chapurlat, Roland
AU - Chevalley, Thierry
AU - Ferrari, Serge
AU - Goltzman, David
AU - Hanley, David A.
AU - Hannan, Marian T.
AU - Khosla, Sundeep
AU - Liu, Ching Ti
AU - Lorentzon, Mattias
AU - Mellstrom, Dan
AU - Merle, Blandine
AU - Nethander, Maria
AU - Rizzoli, René
AU - Sornay-Rendu, Elisabeth
AU - Van Rietbergen, Bert
AU - Sundh, Daniel
AU - Wong, Andy Kin On
AU - Ohlsson, Claes
AU - Demissie, Serkalem
AU - Kiel, Douglas P.
AU - Bouxsein, Mary L.
N1 - Funding Information:
SB is the cofounder of Numerics88 Solutions, which provides estimates of bone strength from HR-pQCT images. JA has received grants and personal fees from Amgen, Eli Lilly, and Merck, grants from Actavis, and personal fees from Agnovis. RC has received grants and personal fees from Amgen, Chugai, and Merck and personal fees from Abbvie, BMS, Lilly, Pfizer, Sanoz, and UCB. DAH has received grants and personal fees from Amgen and grants from Pure North S'Energy Foundation. ML has received personal fees from Amgen, Consilient Health, Lilly, Meda, Radius Health, Renapharma, and UCB Pharma. RR has received personal fees from CNIEL, Danone, Pfizer, Radius Health, and Sandoz. BVR has received personal fees from Scanco Medical. DPK has received personal fees from Springer. All other authors declare no competing interests.
Funding Information:
This work was supported by the National Institutes of Health (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases ( R01AR061445 ) and National Heart, Lung, and Blood Institute Framingham Heart Study ( N01-HC-25195, HHSN268201500001I ). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Additional support was provided by Friends of Hebrew SeniorLife and the Investigator Initiated Studies Program of Merck Sharp & Dohme. The opinions expressed in this work are those of the authors and do not necessarily represent those of Merck. We thank Alyssa B Dufour for providing statistical expertise.
Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2019/1
Y1 - 2019/1
N2 - Background: Although areal bone mineral density (aBMD) assessed by dual-energy x-ray absorptiometry (DXA) is the clinical standard for determining fracture risk, most older adults who sustain a fracture have T scores greater than −2·5 and thus do not meet the clinical criteria for osteoporosis. Importantly, bone fragility is due to low BMD and deterioration in bone structure. We assessed whether indices of high-resolution peripheral quantitative CT (HR-pQCT) were associated with fracture risk independently of femoral neck aBMD and the Fracture Risk Assessment Tool (FRAX) score. Methods: We assessed participants in eight cohorts from the USA (Framingham, Mayo Clinic), France (QUALYOR, STRAMBO, OFELY), Switzerland (GERICO), Canada (CaMos), and Sweden (MrOS). We used Cox proportional hazard ratios (HRs) to estimate the association between HR-pQCT bone indices (per 1 SD of deficit) and incident fracture, adjusting for age, sex, height, weight, and cohort, and then additionally for femoral neck DXA aBMD or FRAX. Findings: 7254 individuals (66% women and 34% men) were assessed. Mean baseline age was 69 years (SD 9, range 40–96). Over a mean follow-up of 4·63 years (SD 2·41) years, 765 (11%) participants had incident fractures, of whom 633 (86%) had femoral neck T scores greater than −2·5. After adjustment for age, sex, cohort, height, and weight, peripheral skeleton failure load had the greatest association with risk of fracture: tibia HR 2·40 (95% CI 1·98–2·91) and radius 2·13 (1·77–2·56) per 1 SD decrease. HRs for other bone indices ranged from 1·12 (95% CI 1·03–1·23) per 1 SD increase in tibia cortical porosity to 1·58 (1·45–1·72) per 1 SD decrease in radius trabecular volumetric bone density. After further adjustment for femoral neck aBMD or FRAX score, the associations were reduced but remained significant for most bone parameters. A model including cortical volumetric bone density, trabecular number, and trabecular thickness at the distal radius and a model including these indices plus cortical area at the tibia were the best predictors of fracture. Interpretation: HR-pQCT indices and failure load improved prediction of fracture beyond femoral neck aBMD or FRAX scores alone. Our findings from a large international cohort of men and women support previous reports that deficits in trabecular and cortical bone density and structure independently contribute to fracture risk. These measurements and morphological assessment of the peripheral skeleton might improve identification of people at the highest risk of fracture. Funding: National Institutes of Health National Institute of Arthritis Musculoskeletal and Skin Diseases.
AB - Background: Although areal bone mineral density (aBMD) assessed by dual-energy x-ray absorptiometry (DXA) is the clinical standard for determining fracture risk, most older adults who sustain a fracture have T scores greater than −2·5 and thus do not meet the clinical criteria for osteoporosis. Importantly, bone fragility is due to low BMD and deterioration in bone structure. We assessed whether indices of high-resolution peripheral quantitative CT (HR-pQCT) were associated with fracture risk independently of femoral neck aBMD and the Fracture Risk Assessment Tool (FRAX) score. Methods: We assessed participants in eight cohorts from the USA (Framingham, Mayo Clinic), France (QUALYOR, STRAMBO, OFELY), Switzerland (GERICO), Canada (CaMos), and Sweden (MrOS). We used Cox proportional hazard ratios (HRs) to estimate the association between HR-pQCT bone indices (per 1 SD of deficit) and incident fracture, adjusting for age, sex, height, weight, and cohort, and then additionally for femoral neck DXA aBMD or FRAX. Findings: 7254 individuals (66% women and 34% men) were assessed. Mean baseline age was 69 years (SD 9, range 40–96). Over a mean follow-up of 4·63 years (SD 2·41) years, 765 (11%) participants had incident fractures, of whom 633 (86%) had femoral neck T scores greater than −2·5. After adjustment for age, sex, cohort, height, and weight, peripheral skeleton failure load had the greatest association with risk of fracture: tibia HR 2·40 (95% CI 1·98–2·91) and radius 2·13 (1·77–2·56) per 1 SD decrease. HRs for other bone indices ranged from 1·12 (95% CI 1·03–1·23) per 1 SD increase in tibia cortical porosity to 1·58 (1·45–1·72) per 1 SD decrease in radius trabecular volumetric bone density. After further adjustment for femoral neck aBMD or FRAX score, the associations were reduced but remained significant for most bone parameters. A model including cortical volumetric bone density, trabecular number, and trabecular thickness at the distal radius and a model including these indices plus cortical area at the tibia were the best predictors of fracture. Interpretation: HR-pQCT indices and failure load improved prediction of fracture beyond femoral neck aBMD or FRAX scores alone. Our findings from a large international cohort of men and women support previous reports that deficits in trabecular and cortical bone density and structure independently contribute to fracture risk. These measurements and morphological assessment of the peripheral skeleton might improve identification of people at the highest risk of fracture. Funding: National Institutes of Health National Institute of Arthritis Musculoskeletal and Skin Diseases.
UR - http://www.scopus.com/inward/record.url?scp=85058917448&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058917448&partnerID=8YFLogxK
U2 - 10.1016/S2213-8587(18)30308-5
DO - 10.1016/S2213-8587(18)30308-5
M3 - Article
C2 - 30503163
AN - SCOPUS:85058917448
SN - 2213-8587
VL - 7
SP - 34
EP - 43
JO - The Lancet Diabetes and Endocrinology
JF - The Lancet Diabetes and Endocrinology
IS - 1
ER -